Current Status and Research Progress of Immunotherapy for Melanoma

Cuihua FANG; Maohua PAN; Longcan ZHOU; Yucheng QIN; Yaming HUANG; Jia MA; Xi CHEN; Zhaoqing YANG

doi:10.12259/j.issn.2095-610X.S20230519

Volume 44 Issue 5

May 2023

Turn off MathJax

Article Contents

Article Navigation > Journal of Kunming Medical University > 2023 > 44(5): 175-179

Cuihua FANG, Maohua PAN, Longcan ZHOU, Yucheng QIN, Yaming HUANG, Jia MA, Xi CHEN, Zhaoqing YANG. Current Status and Research Progress of Immunotherapy for Melanoma[J]. Journal of Kunming Medical University, 2023, 44(5): 175-179. doi: 10.12259/j.issn.2095-610X.S20230519

Citation:

Cuihua FANG, Maohua PAN, Longcan ZHOU, Yucheng QIN, Yaming HUANG, Jia MA, Xi CHEN, Zhaoqing YANG. Current Status and Research Progress of Immunotherapy for Melanoma[J]. Journal of Kunming Medical University, 2023, 44(5): 175-179. doi: 10.12259/j.issn.2095-610X.S20230519

Citation:

PDF( 544 KB)

Current Status and Research Progress of Immunotherapy for Melanoma

doi: 10.12259/j.issn.2095-610X.S20230519

1.
Medical College of Yunnan University of Economics and Management，Kunming Yunnan 650106
2.
Dept. of Internal Medicine，Shanglin County People’s Hospital，Shanglin Guangxi 530500
3.
Basic College of Kunming Medical University， Kunming Yunnan 650500，China

Received Date: 2023-01-24
Available Online: 2023-05-11
Publish Date: 2023-05-25

Abstract

Abstract

Melanoma is a highly lethal skin malignant tumor. Although years of clinical studies have proved that there are various methods for its treatment, such as surgery, chemotherapy, radiotherap, targeted therapy, etc., due to its low sensitivity, strong toxic and side effects, and poor efficacy, in view of the wide application of immunotherapy in the treatment of tumor diseases, the author reviewed the progress of immunotherapy of melanoma in recent years.
- Melanoma,
- Immunotherapy,
- Cytokines,
- Tumor vaccines,
- Plasmodium

FullText(HTML)

References(29)

References

[1]	Bray F,Ferlay J,Soerjomataram I,et al. Global cancer statistics 2018:Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA:A Cancer Journal for Clinicians,2018,68(6):394-424. doi: 10.3322/caac.21492
[2]	Carrs S,Smith C,Wermberg J. Epidemiology and risk factors melanoma[J]. Surg Clin North Am,2020,100(1):1-12. doi: 10.1016/j.suc.2019.09.005
[3]	Patel H,Yacooub N,Mishra R,et al. Current advances in the treatment of BRAF-mutant melanoma[J]. Cancers Basel,2020,12(2):482-491.
[4]	Zhu Z,Liu W,Gotileb V. The rapidly evolving therapies for advanced melanoma-towards immunotherapy,molecular targeted therapy,and beyond[J]. Crit Rev Oncol Hematol,2016,99(1):91-99.
[5]	Davis L E,Shalin S C,Tackett A J. Current state of melanoma diagnosis and treatment[J]. Cancer Biol Ther,2019,20(11):1366-1379. doi: 10.1080/15384047.2019.1640032
[6]	Lugobic-mihic L,Ćesic D,Vukovic P,et al. Melanoma development:Current knowledge on melanoma pathogenesis[J]. Acta Dermatovenerol Croat,2019,27(3):163-168.
[7]	Babcan A. Eroglu Z,Treatment options for advanced melanoma after anti-PD-1 therapy[J]. Current Oncology Reports,2020,22(4):38-42. doi: 10.1007/s11912-020-0894-z
[8]	Haanen J,Ernstoffff M S,Wangf Y,et al. Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy:Review of the literature and personalized risk-based prevention strategy[J]. Annals of Oncology,2020,31(6):724-744. doi: 10.1016/j.annonc.2020.03.285
[9]	Hmaidm O,Ismil V,Puzanov I. Intratumoral immunotherapy-update 2019[J]. The Oncologist,2020,25(3):e423-e438. doi: 10.1634/theoncologist.2019-0438
[10]	Kremenovic M,Schenk M,Leed J. Clinical and molecular insights into BCG immunotherapy for melanoma[J]. Journal of Internal Medicine,2020,6(288):1-16.
[11]	Twitty C G,Huppert L A,Daud A I. Prognostic biomarkers for melanoma immunotherapy[J]. Current Oncology Reports,2020,22(3):25-32. doi: 10.1007/s11912-020-0886-z
[12]	Ellithi M,Elnair R,Chang G V,et al. Toxicities of immune checkpoint inhibitors: It is-ending adverse reactions and more[J]. Cureus,2020,12(2):e6935-e6943.
[13]	郭军,崔传亮. 皮肤黑色素瘤瘤体内治疗进展[J]. 肿瘤医学论坛,2016,21(6):556-559.
[14]	Mcomasters K M,Egger M E,Edwards M J,et al. Final results of the sunbelt melanoma trial: A multi-institutional prospective randomized phase iii study evaluating the role of adjuvant high-dose interferon alfa-2b and completion lymph node dissection for patients staged by sentinel lymph node biopsy[J]. J Clin Oncol,2016,37(1):S35-45.
[15]	Zarstsky J M,Garciadiaz A,Shin D S,et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma[J]. N Engl J Med,2016,375(9):819-829. doi: 10.1056/NEJMoa1604958
[16]	Eggermint A M M,Blank C U,Mandala M,et al. Longer follow-up confirms recurrence-free survival benefit of adjuvant pembrolizu mab in high-risk stage Ⅲ melanoma:Updated results from the EORTC 1325-MG/KEYNOTE-054 trial[J]. J Clin Oncol,2020,38(33):3925-3936. doi: 10.1200/JCO.20.02110
[17]	Ascierto P A,Vecchiom D,Mandala M,et al. Adjuvant nivolumab versus ipilimumab in resected stage ⅢB-C and stage Ⅳ melanoma (CheckMate 238): 4-year results from a multicentre,double-blind,randomised,controlled,phase 3 trial[J]. Lancet Oncol,2020,21(11):1465-1477. doi: 10.1016/S1470-2045(20)30494-0
[18]	Yokota K,Uchi H,Uhara H,et al. Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage Ⅲ/Ⅳ melanoma:Japanese subgroup analysis from the phase 3 checkmate 238 study[J]. J Dermatol,2019,46(12):1197-1201. doi: 10.1111/1346-8138.15103
[19]	Lohmueller J,Finn O J. Current modalities in cancer immunotherapy: Immunomodulatory antibodies,CARs and vaccines[J]. Pharmacol Ther,2017,3(178):31-47.
[20]	Ott P A,Hu Z,Keskin D B,et al. An immunogenic personal neoantigen vaccine for patients with melanoma[J]. Nature,2017,547(7662):217-221. doi: 10.1038/nature22991
[21]	Williegen W W,Bloemendal M,Gerritsen W R,et al. Dendritic cell cancer therapy: Vaccinating the right patient at the right time[J]. Frontiers in Immunology,2018,9(15):22-65. doi: 10.3389/fimmu.2018.00022
[22]	Javed A, Sato S, Sato T, Autologous melanoma cell vaccine using monocyte-derived dendritic cells （NBS20/eltrapuldencel-T）[J]. Future Oncology, 2016, 12（6）: 751–762.
[23]	Merhavi-shohame E,Ihzhaki O,Markel G,et al. Adoptive cell therapy for metastatic melanoma[J]. Cancer J,2017,23(1):48-53. doi: 10.1097/PPO.0000000000000240
[24]	Andersen R,Donia M,Ellebaek E,et al. Long-lasting complete responses in patients with metastatic melanoma after adoptive cell therapy with tumor-infiltrating lymphocytes and an attenuated IL-2 regimen[J]. Clin Cancer Res,2016,22(15):3734-3745. doi: 10.1158/1078-0432.CCR-15-1879
[25]	Qian X Y,Pan Y L. Current status of immunotherapy for malignant melanoma[J]. Zhejiang Medical Journal,2016,3(10):8-18.
[26]	Chen X P,Qin L,Hu W,et al. The mechanisms of action of plasmodium infection against cancer[J]. Cell Commun Signal,2021,19(74):8-9.
[27]	Yang Y,Liu Q,Lu J,et al. Exosomes from plasmodium-infected hosts inhibit tumor angiogenesis in a murine lewis lung cancer model[J]. Oncogenesis,2017,6(6):e351-e359. doi: 10.1038/oncsis.2017.52
[28]	Wang B F,Li Q Y,Chen X P,et al. Plasmodium infection inhibits tumor angiogenesis through effects on tumor-associated macrophages in a murine implanted hepatoma model[J]. Cell Communication and Signaling,2020,18(157):17-32.
[29]	Bibbo S,Ianiro G,Giambo F,et al. Role of gut microbiome on immunotherapy efficacy in melanoma[J]. Hum Vaccines Immunother,2021,5(17):1-6.

Relative Articles(20)

Relative Articles

[1]	Shibing QIAN, Huiping SHI, Yanqiu LI, Rongyu YANG, Kaiwen DUAN. Research Progress on Osteogenic Differentiation of Apical Papilla Stem Cells. Journal of Kunming Medical University, 2024, 45(9): 168-173. doi: 10.12259/j.issn.2095-610X.S20240926
[2]	Fen LI, Jie ZHAO, Haixi ZHANG, Lin ZHANG, Xuezhong GU. The Correlation of Iron Metabolism Indexes，Cytokines，and Liver Function in Patients with Hemophagocytic Syndrome. Journal of Kunming Medical University, 2024, 45(11): 110-116. doi: 10.12259/j.issn.2095-610X.S20241115
[3]	Jianfang DONG, Xijing YIN, Zucong CHEN, Xuefei ZHANG, Zeping ZHOU. Research progress of immune-related molecules in primary immune thrombocytopenia. Journal of Kunming Medical University, 2023, 44(1B): 1-6.
[4]	Xilan WU, Hong SHEN, Susheng SHI, Zhihui ZHANG, Lei GUO, Fang WANG. The Expression of PD-L1, BRAF^V600E, CD68 Protein and the Significance of Tumor Infiltrating Lymphocytes in the Diagnosis of Malignant Melanoma. Journal of Kunming Medical University, 2022, 43(9): 13-18. doi: 10.12259/j.issn.2095-610X.S20220923
[5]	Kun ZHAO, Yun XIAO, Chun YANG, Zhiling YAN, Minna DONG, Bingquan XIANG, Mingyao XIAO. Protective Effect of Interleukin-4 in Lipopolysaccharide-induced Acute Lung Injury Models. Journal of Kunming Medical University, 2022, 43(8): 41-46. doi: 10.12259/j.issn.2095-610X.S20220805
[6]	Haixia ZHANG, Lei LI, Lei JIN, Peijing YE, Chuanzheng SUN. Clinical Features of 1,203 Melanoma Cases in Yunnan Cancer Hospital. Journal of Kunming Medical University, 2022, 43(8): 56-60. doi: 10.12259/j.issn.2095-610X.S20220808
[7]	Xing LIU, Hai-wen LI, Hong-li HUANG, Lin-jun SHEN, Le ZHANG, Xiang-fang LIU, Wen-lin ZHANG, Lu WANG. Effects of Probiotics Enhanced Enteral Nutrition on Gastrointestinal Function and Cytokines in Patients with Severe Acute Pancreatitis. Journal of Kunming Medical University, 2021, 42(11): 81-86. doi: 10.12259/j.issn.2095-610X.S20211116
[8]	Jin-rong YANG, Kun WU, Bo NIE, Zhen-xin HE, Yu-yu YANG, Jie SUN, Yun ZENG. Clinical Features of Adult HPS and the Correlation between Cytokine Levels and Prognosis. Journal of Kunming Medical University, 2021, 42(12): 51-58. doi: 10.12259/j.issn.2095-610X.S20211220
[9]	Wei-sha ZHOU, Le ZHANG, Jing PENG, Shou-kun CHEN, Meng-jun LIU, Xiao FU, Zhi-fei TANG, Yun-xuan YUE. Effect of Plasma Exchange with Double Plasma Molecular Adsorption on Cytokines in Autoimmune Hepatitis with Liver Failure. Journal of Kunming Medical University, 2021, 42(4): 73-77. doi: 10.12259/j.issn.2095-610X.S20210414
[10]	Wei-jia ZHAO, Hong-bin LI, Zong-han CHEN. Evaluation of Peripheral Blood Cytokine Levels before and after Psoriasis Treatment with Narrow-spectrum UVB Combined with Carpotriol. Journal of Kunming Medical University, 2020, 41(12): 99-103. doi: 10.12259/j.issn.2095-610X.S20201227
[11]	Fan Xu , Feng Yu Ran , Zhu Mei . . Journal of Kunming Medical University, 2019, 40(11): 1-5.
[12]	Qiu Yu Zhen . The Research Progress of Immune Gene Therapy on the Treatment of Multiple myeloma. Journal of Kunming Medical University,
[13]	Zhang Yang . . Journal of Kunming Medical University,
[14]	Xue En Zhong . . Journal of Kunming Medical University,
[15]	Yang Jing . . Journal of Kunming Medical University,
[16]	Yang De Xing . . Journal of Kunming Medical University,
[17]	Zhang Zhen Guang . . Journal of Kunming Medical University,
[18]	Li Yu Xiao . . Journal of Kunming Medical University,
[19]	Zhou Yi Zhong . . Journal of Kunming Medical University,
[20]	Wu Shang Min . . Journal of Kunming Medical University,